<DOC>
	<DOCNO>NCT02175277</DOCNO>
	<brief_summary>This phase 3b , multi-centre , open-label , single-arm companion study MDS 20090160 study treatment anaemic subject MDS . Subjects complete active-treatment period darbepoetin alfa MDS 20090160 study meet eligibility criterion may enrol study continue treatment darbepoetin alfa 73 week progression acute myelogenous leukemia ( AML ) , whichever occur first .</brief_summary>
	<brief_title>Darbepoetin Alfa MDS Companion Protocol</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subject subject 's legally acceptable representative provide informed consent prior studyspecific activities/ procedure initiate ; Subject must continue long term follow within parent study ( 20090160 ) ; Subject must ongoing clinically relevant erythroid response assess Investigator use current response criterion ( ie , International Working Group ( IWG ) response criterion ) ; Transfusion dependence define receive total â‰¥ 4 unit red blood cell ( RBC ) transfusion previous 8week period prior enrolment ; Known diagnosis acute myelogenous leukemia ( AML ) marrow collagen fibrosis ; Known refractory anaemia excess blast2 ( RAEB2 ) ; Known diagnosis intermediate2 high risk MDS per International Prognostic Scoring System ( IPSS ) ; Subjects receive thrombopoiesisstimulating factor ( eg , eltrombopag , romiplostim ) MDS 20090160 study plan receive agent study ; Other protocol define inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Darbepoetin alfa</keyword>
	<keyword>low risk MDS</keyword>
	<keyword>intermediate-1 risk MDS</keyword>
	<keyword>International Prognostic Scoring System ( IPSS )</keyword>
</DOC>